Table 3

Factors associated with a significant change in voriconazole concentration identified from multiple linear regression analysisa

Model termCoefficient95% Confidence intervalP value
LowerUpper
Oral administrationb−1.348−1.741−0.955<0.01
Age (yr)c0.0260.0170.036<0.01
Weight (kg)−0.028−0.038−0.018<0.01
Daily dose (mg)0.0050.0030.006<0.01
Concomitant medication
    CYP2C19 inducerd−2.367−3.181−1.553<0.01
    Prednisone/prednisolone−1.012−1.346−0.678<0.01
    Methylprednisolone−1.833−2.445−1.221<0.01
    Dexamethasone−1.245−1.991−0.500<0.01
    Omeprazole1.1410.5751.706<0.01
    Pantoprazole0.6850.3301.041<0.01
    Esomeprazole1.0090.1921.826<0.05
    Rabeprazole1.4140.8002.028<0.01
  • a R2 = 0.24; n = 736 concentration measurements.

  • b Compared to intravenous administration.

  • c Age at time of first voriconazole concentration measurement.

  • d Phenytoin or rifampin.